Stifel Financial Corp Grows Position in Insulet Co. (NASDAQ:PODD)

Stifel Financial Corp boosted its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 167.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,126 shares of the medical instruments supplier's stock after purchasing an additional 17,599 shares during the period. Stifel Financial Corp's holdings in Insulet were worth $7,343,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of PODD. Virtu Financial LLC purchased a new position in Insulet during the third quarter worth approximately $616,000. Wilmington Savings Fund Society FSB purchased a new position in Insulet during the third quarter worth approximately $114,000. Tidal Investments LLC increased its position in shares of Insulet by 5.2% in the third quarter. Tidal Investments LLC now owns 9,365 shares of the medical instruments supplier's stock worth $2,180,000 after acquiring an additional 466 shares in the last quarter. Synovus Financial Corp increased its position in shares of Insulet by 36.1% in the third quarter. Synovus Financial Corp now owns 2,929 shares of the medical instruments supplier's stock worth $682,000 after acquiring an additional 777 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in shares of Insulet in the third quarter worth $202,000.

Insulet Trading Down 0.5 %

Insulet stock opened at $259.52 on Tuesday. The company has a market cap of $18.23 billion, a P/E ratio of 44.82, a PEG ratio of 3.62 and a beta of 1.30. The firm's 50-day moving average is $259.72 and its 200-day moving average is $262.09. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. On average, equities analysts expect that Insulet Co. will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on PODD shares. Wells Fargo & Company set a $322.00 price objective on shares of Insulet in a research report on Monday. Raymond James reaffirmed an "outperform" rating and set a $328.00 price target (up from $294.00) on shares of Insulet in a report on Friday, February 21st. Piper Sandler raised their price target on shares of Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Canaccord Genuity Group raised their price target on shares of Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a report on Friday, February 21st. Finally, Citigroup raised their price target on shares of Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a report on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $292.06.

Insider Activity at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares in the company, valued at $888,525. This represents a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.47% of the stock is currently owned by insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.